Traws Pharma, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
TRAW$0.23-6.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · Six Months Ended June 30, · | |||||||
| · 2025 · 2024 | |||||||
| Operating activities: | | | | | | | |
| Net income (loss) | | $20,575,000 | | $(128,126,000) | | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | |
| Acquired in-process research and development | | | — | | | 117,464,000 | |
| Change in fair value of warrant liability | | | (26,659,000) | | | — | |
| Depreciation and amortization | | 2,000 | | 8,000 | | ||
| Stock-based compensation | | 266,000 | | 713,000 | | ||
| Changes in assets and liabilities: | | | | | | | |
| Receivables | | 442,000 | | — | | ||
| Prepaid expenses and other current assets | | 882,000 | | 54,000 | | ||
| Other assets | | | — | | | — | |
| Accounts payable | | (3,605,000) | | 555,000 | | ||
| Accrued expenses and other current liabilities | | (528,000) | | (4,831,000) | | ||
| Deferred revenue | | (2,791,000) | | (113,000) | | ||
| Net cash used in operating activities | | (11,416,000) | | (14,276,000) | | ||
| | | | | | | | |
| Investing activities: | | | | | | | |
| Cash paid for acquisition, net of cash acquired | | | — | | | (3,648,000) | |
| Net cash used in investing activities | | — | | (3,648,000) | | ||
| | | | | | | | |
| Financing activities: | | | | | | | |
| Proceeds from sale of common stock pursuant to the ATM | | | 3,379,000 | | | — | |
| Proceeds from sale of common stock with the private placement, net of expenses | | | — | | | 13,999,000 | |
| Payment of offering costs | | | (287,000) | | | — | |
| Proceeds from exercised prefunded warrants | | | 16,000 | | | — | |
| Net cash provided by financing activities | | 3,108,000 | | 13,999,000 | | ||
| Effect of foreign currency translation on cash | | 51,000 | | (10,000) | | ||
| Net decrease in cash and cash equivalents | | (8,257,000) | | (3,935,000) | | ||
| Cash and cash equivalents at beginning of period | | 21,338,000 | | 20,821,000 | | ||
| Cash and cash equivalents at end of period | | $13,081,000 | | $16,886,000 | | ||
| Supplemental disclosure of cash flow information: | | | | | | | |
| Deferred offering costs in accounts payable | | $178,000 | | $— | | ||
| Reclassification of warrant liability upon exercise of prefunded warrants and amended warrant agreements | | $15,827,000 | | $— | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.